Reduction of Donor Blood Transfusion in Patients During Surgery for in Patients with Locally Advanced Kidney Cancer
This clinical trial evaluates which methods of blood transfusion are best for patients undergoing kidney surgery. Allogenic (donor) blood transfusion has been shown to cause more side effects (with the lungs, immune system, and circulation, for example) as well as worse cancer outcomes. These concerns have encouraged methods to decrease allogenic blood transfusion. Blood transfusion is defined as a medical treatment that replaces blood that is lost during surgery and is causing changes in blood pressure or heart rate due to that loss. There are two sources of blood for transfusion, allogenic and autologous. Allogenic blood is blood that is provided from healthy blood donors. Autologous blood is provided from the patient for their own use. Techniques that can reduce the need for allogenic blood transfusion include acute normovolemic hemodilution and cell salvage, which use the patient's own blood (autologous) in transfusion. This study aims to reduce the number of units of allogenic (donated) blood that is transfused.